EL7.AI
StocksMedium•17 November 2026•
4 min read

Vivos Revenue Jumps 24% Quarter on Quarter to $6.4 Million as Net Loss Narrows

Key Facts

1Third-quarter revenue was $6.4 million, up 24% from second-quarter revenue of $5.2 million.
2The net loss was $2.0 million, compared with $5.4 million a year earlier, and included about $2.9 million in income from reversing an employee retention credit liability.
3Quarterly operating expenses fell 17% to $7.2 million from $8.7 million.
4Cash and cash equivalents totaled $247,000 on September 30, 2026.
5VVOS shares fell 16.12% in the November 16, 2026 session.

Vivos Therapeutics reported revenue of $6.4 million in the third quarter of 2026, up 24% from the second quarter, while its net loss narrowed to $2.0 million from $5.4 million a year earlier, according to its results filing with the U.S. Securities and Exchange Commission. But the year-over-year comparison included about $2.9 million in other income from the reversal of a prior liability related to the employee retention credit. The figures alone therefore do not reflect a comparable improvement in operating performance, as the quarterly operating loss was $3.9 million. The disclosure did not include analyst estimates, and claims that results exceeded them could not be verified. For the nine months ended September 30, revenue reached $16.7 million, compared with $13.6 million in the same period of 2025.

Quarterly revenue growth came from services, which rose 1% to $4.6 million compared with the third quarter of 2025. By contrast, product revenue fell to $1.8 million from $2.2 million. The company attributed the decline to its strategic shift away from selling devices to dentists under the Vivos Integrated Provider, or VIP, program. Total third-quarter revenue was $6.4 million, compared with $6.8 million in the third quarter of the prior year, according to figures in the company’s statement. For the nine months, revenue rose to $16.7 million from $13.6 million.

Quarterly operating expenses fell 17% to $7.2 million from $8.7 million a year earlier. The reduction included $1.4 million in general and administrative expenses, driven mainly by lower professional fees, equipment maintenance and office expenses, as well as a decline in marketing and sales costs. The chief executive said general and administrative expenses and marketing and sales expenses fell by a combined $1.6 million, and that the company eliminated an estimated at least $5 million in annual operating costs. The cost cuts helped narrow the quarterly operating loss 18% to $3.9 million from $4.7 million in the third quarter of 2025. However, the operating loss for the nine months widened to $15.3 million, compared with $13.5 million in the same period.

Available cash remained limited at the end of September, with cash and cash equivalents of $247,000 on September 30, 2026, compared with $2.029 million on December 31, 2025. The balance sheet, meanwhile, showed shareholders’ equity of $2.360 million, after a deficit of $1.490 million at the end of 2025. Management said it converted about $6.1 million of senior secured debt into equity during 2026. After the quarter ended, the company completed the SOD Sciences transaction on October 16. Nasdaq informed the company on October 20 that it had regained compliance with the minimum shareholders’ equity requirement, with monitoring to continue.

Management outlined clinical and operational initiatives that it said are intended to expand revenue sources and improve margins. They include EEG testing, treatment for insomnia and sleep disorders unrelated to sleep apnea, distribution and setup of PAP and CPAP therapies, and remote monitoring of CPAP users. The company also cited renegotiating payer contracts as part of the initiatives. It said it expects these steps to begin contributing to revenue and margins in the fourth quarter of 2026, with their impact increasing during 2027. These are management’s expectations, not achieved results.

The company’s shares, VVOS, closed at $0.0822 on November 16, 2026, down 16.12% in the session, according to EL7 and Investing.com data. On the same day, management was scheduled to hold a call to discuss the results and strategic initiatives at 5:00 p.m. Eastern Time. The company said a replay of the call would remain available through November 30, 2026. This follows the quarterly results announcement, which showed revenue growth from the previous quarter and a net loss below its year-earlier level, alongside an accounting impact related to the reversal of an employee retention credit liability. The disclosure does not provide analyst estimates that would establish whether results exceeded market expectations.

Open on chart